Table 1.
Characteristics of patients undergoing female-to-male allo-HCT
| Del(Y) (n = 155) | Y present (n = 4149) | P | |
|---|---|---|---|
| Age, y | .28 | ||
| ≤50 | 58 (37.4) | 1740 (41.9) | |
| >50 | 97 (62.6) | 2409 (58.1) | |
| Disease type | <.001 | ||
| AML | 116 (74.8) | 2350 (56.6) | |
| ALL | 15 (9.7) | 855 (20.6) | |
| MDS | 24 (15.5) | 790 (19.0) | |
| MPN | 0 (0.0) | 154 (3.7) | |
| DRI | <.001 | ||
| Low | 25 (16.1) | 139 (3.4) | |
| Intermediate | 44 (28.4) | 2379 (57.3) | |
| High | 45 (29.0) | 1363 (32.9) | |
| Very high | 41 (26.5) | 268 (6.5) | |
| HCT-CI | <.001 | ||
| 0-1 | 90 (58.1) | 2964 (71.4) | |
| ≥2 | 64 (41.3) | 1151 (27.7) | |
| PS | .11 | ||
| 0-1 | 135 (87.1) | 3773 (90.9) | |
| 2-4 | 20 (12.9) | 369 (8.9) | |
| Donor type | .93 | ||
| Matched related | 38 (24.5) | 982 (23.7) | |
| Matched unrelated | 24 (15.5) | 713 (17.2) | |
| Mismatched related | 14 (9.0) | 432 (10.4) | |
| Mismatched unrelated | 73 (47.1) | 1916 (46.2) | |
| Donor source | .44 | ||
| Bone marrow | 42 (27.1) | 1375 (33.1) | |
| Peripheral blood | 49 (31.6) | 1207 (29.1) | |
| Cord blood | 64 (41.3) | 1559 (37.6) | |
| Conditioning regimen | .33 | ||
| MAC | 100 (64.5) | 2835 (68.3) | |
| RIC | 55 (35.5) | 1313 (31.6) | |
| GVHD prophylaxis | .21 | ||
| CsA based | 38 (24.5) | 1251 (30.2) | |
| TAC based | 113 (72.9) | 2826 (68.1) | |
| Other | 4 (2.6) | 71 (1.7) | |
| T-cell in vivo depletion | .60 | ||
| Yes | 14 (9.0) | 443 (10.7) | |
| No | 141 (91.0) | 3706 (89.3) |
Data are presented as n (%).
CsA, cyclosporine; PS, performance status; TAC, tacrolimus.